Cixutumumab
Drug
Cixutumumab is a human monoclonal antibody for the treatment of solid tumors.
This drug was developed by ImClone Systems, since acquired by Eli Lilly, using phage display technology from Dyax. Wikipedia
Target: IGF-1 receptor